WATERTOWN, Mass., Oct. 13, 2011 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a clinical stage infectious disease biopharmaceutical company, announced today the award of a contract from the National …
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
ABBOTT PARK, Ill., and WATERTOWN, Mass., Apr. 4, 2011 — Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor …